News archive
Showing 750 results
May 2017
-
Media Release
Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
Physicians now have the option of prescribing Kisqali and Femara together in one convenient co-pack Co-Pack allows patients ability to obtain Kisqali and Femara with a single co-pay Approval comes… -
Media Release
Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
April 2017
-
Media Release
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada
Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the U.S.; Novartis to gain exclusive rights in CanadaNovartis retains commercial rights in rest of world; Amgen retains commercial rights… -
Media Release
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada
-
Media Release
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
-- Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)-- R/r DLBCL, an… -
Media Release
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
March 2017
-
Media Release
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cellsNovartis made an early commitment to the… -
Media Release
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
-
Media Release
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced… -
Media Release
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
-
Media Release
Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
- 94% of patients regained their PASI 75 response and the majority re-achieved their PASI 90 or 100 response after 16 weeks of Cosentyx 300 mg retreatment(1)- Patients may need to pause treatment due… -
Media Release
Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause